Loading…
Enhabit, Inc. provides home health and hospice services in the United States. The Home Health segment offers nursing care; physical, occupational, and speech therapy; medical and social work; and home health aide services. This segment also provides patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery or injury, and respiratory diseases; and counseling for patients and their families regarding financial, personal, and social concerns that arise from a patient's health-related problems. Its Hospice segment offers nursing care; pain and symptom management; palliative and dietary counseling; social worker visits; spiritual counseling; and family member bereavement counseling to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is headquartered in Dallas, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.1B | $58M | $-5M | $66M | -0.9% | 2.4% | -97.1% |
| 2024 | $1.0B | $-84M | $-156M | $47M | -29.8% | -1.1% | 94.0% |
| 2023 | $1.0B | $-17M | $-81M | $45M | -12.0% | -2.3% | 99.3% |
| 2022 | $1.1B | $23M | $-40M | $73M | -5.4% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,071.10 | 1,046.30 | 1,034.80 | 1,060 |
| Operating Revenue | - | 1,071.10 | 1,046.30 | 1,034.80 | 1,060 |
| Cost Of Revenue | - | 525.60 | 535.60 | 530.80 | 540.20 |
| Gross Profit | - | 545.50 | 510.70 | 504 | 519.80 |
| Operating Expense | - | 447.90 | 472.50 | 457.40 | 456 |
| Selling General And Administration | - | 414.90 | 441.60 | 425.90 | 433.50 |
| Total Expenses | - | 973.50 | 1,008.10 | 988.20 | 996.20 |
| Operating Income | - | 97.60 | 38.20 | 46.60 | 63.80 |
| Total Operating Income As Reported | - | -11.40 | -47.60 | -115.10 | 16.10 |
| EBITDA | - | 22.50 | -16.50 | -83.60 | 57.90 |
| Normalized EBITDA | - | 131.50 | 69.30 | 78.10 | 105.60 |
| EBIT | - | -10.50 | -47.40 | -115.10 | 35.40 |
| Interest Income | - | - | 0 | 0 | 0.20 |
| Interest Expense | - | 15 | 43 | 42.90 | 34 |
| Net Interest Income | - | -15 | -43 | -42.90 | -33.80 |
| Other Non Operating Income Expenses | 4.80 | 0.90 | 0.20 | - | 19.10 |
| Other Income Expense | - | -108.10 | -85.60 | -161.70 | -28.60 |
| Interest Income Non Operating | - | - | 0 | 0 | 0.20 |
| Interest Expense Non Operating | - | 15 | 43 | 42.90 | 34 |
| Net Non Operating Interest Income Expense | - | -15 | -43 | -42.90 | -33.80 |
| Pretax Income | - | -25.50 | -90.40 | -158 | 1.40 |
| Tax Provision | - | 12.80 | -11.40 | -4 | 4 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -22.89 | -10.82 | -4.09 | -10.02 |
| Net Income Continuous Operations | - | -38.30 | -79 | -154 | -2.60 |
| Net Income From Continuing And Discontinued Operation | - | -40.40 | -80.50 | -156.20 | -4.60 |
| Net Income From Continuing Operation Net Minority Interest | - | -40.40 | -80.50 | -156.20 | -4.60 |
| Net Income | - | -40.40 | -80.50 | -156.20 | -4.60 |
| Net Income Common Stockholders | - | -40.40 | -80.50 | -156.20 | -4.60 |
| Net Income Including Noncontrolling Interests | - | -38.30 | -79 | -154 | -2.60 |
| Normalized Income | - | 45.71 | -5.52 | 1.41 | 33.08 |
| Diluted NI Availto Com Stockholders | - | -40.40 | -80.50 | -156.20 | -4.60 |
| Basic Average Shares | 49.90 | 49.60 | 49.90 | 50.20 | - |
| Diluted Average Shares | 49.90 | 49.70 | 49.90 | 50.20 | - |
| Reconciled Depreciation | - | 33 | 30.90 | 31.50 | 22.50 |
| Reconciled Cost Of Revenue | - | 525.60 | 535.60 | 530.80 | 540.20 |
| Total Unusual Items | - | -109 | -85.80 | -161.70 | -47.70 |
| Total Unusual Items Excluding Goodwill | - | -109 | -85.80 | -161.70 | -47.70 |
| Minority Interests | - | -2.10 | -1.50 | -2.20 | -2 |
| Special Income Charges | - | -109 | -85.80 | -161.70 | -47.70 |
| Impairment Of Capital Assets | - | 109 | 85.80 | 161.70 | 47.70 |
| Depreciation Amortization Depletion Income Statement | - | 33 | 30.90 | 31.50 | 22.50 |
| Depreciation And Amortization In Income Statement | - | 33 | 30.90 | 31.50 | 22.50 |
| General And Administrative Expense | - | 414.90 | 441.60 | 425.90 | 433.50 |
| Other Gand A | - | 414.90 | 441.60 | 425.90 | 433.50 |
| Earnings From Equity Interest | 0.60 | 0 | 0 | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Enhabit, Inc.this co. | EHAB | $707M | -153.68 | 1.32 | -0.9% | 20.09 |
| HealthStream, Inc. | HSTM | $739M | 40.28 | 2.09 | 5.2% | 11.26 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 | 8.91 | -14.9% | -46.77 |
| Solid Biosciences Inc. | SLDB | $713M | -4.09 | 3.96 | -96.8% | -3.80 |
| CBLL | CBLL | $711M | -13.32 | 4.58 |
| - |
| - |
| - |
| - |
| -34.4% |
| -13.81 |
| Allogene Therapeutics, Inc. | ALLO | $704M | -3.69 | 2.41 | -65.3% | -4.15 |
| Aura Biosciences, Inc. | AURA | $703M | -6.62 | 5.13 | -77.6% | -5.92 |
| Candel Therapeutics, Inc. | CADL | $679M | -17.79 | 13.08 | -73.5% | -17.28 |
| Design Therapeutics, Inc. | DSGN | $672M | -9.63 | 3.16 | -32.8% | -8.33 |
| Peer Median | - | -8.12 | 4.27 | -49.8% | -7.12 | |